Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $15
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $21 to $15.
Read original at benzingaStocks · News reference
Full Transcript: Cellebrite DI Q2 2026 Earnings Call
Cellebrite DI (NASDAQ:CLBT) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 2:03 PM
- Checked
- Aug 13, 2026, 2:03 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.
Read original at benzingaDA Davidson Maintains Buy on Cellebrite DI, Lowers Price Target to $15
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $22 to $15.
Read original at benzingaNeedham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.
Read original at benzinga